9/26/2008

The European Medicines Agency's negative review of Vimpat's use in diabetic neuropathic pain has prompted UCB SA to drop its EU application for the expanded use of the epilepsy treatment. A UCB spokeswoman said the Belgian drugmaker plans to conduct an additional clinical study "to further substantiate the magnitude" of Vimpat's effects in patients with diabetic neuropathic pain.

Full Story:
Reuters

Related Summaries